Table 2. Comparison of serum levels of biomarkers of bone metabolism in patients with PDB according to disease activity and current treatment (defined as use of oral bisphosphonates in the last six months or zoledronic acid in the last 12 months).
RANKL - receptor activator of nuclear factor kappa-Β ligand, DKK-1 - Dickkopf-related protein-1, sFRP-1 - soluble frizzled-related protein 1, PDB - Paget’s disease of bone, OPG - osteoprotegerin, BAP - bone-specific alkaline phosphatase
| Disease activity | Current treatment | ||||||
| Active (n = 39) | Inactive (n = 18) | p value | Yes (n = 18 ) | No (n = 39) | p value | ||
| RANKL (pg/ml) | 110.27 (214.40) | 158.83 (481.29) | p = 0.598 | 69.66 (196.66) | 151.43 (361.79) | p = 0.374 | |
| Osteoprotegerin (pg/ml) | 278.60 (328.49) | 168.88 (184.55) | p = 0.275 | 250.42 (202.24) | 249.27 (327.98) | p = 0.989 | |
| DKK-1 (pg/ml) | 916.98 (921.26) | 2113,.7 (2493.30) | p = 0.011 | 964.74 (739.30) | 1429.54 (1922.34) | p = 0.328 | |
| sFRP-1 (pg/ml) | 27.23 (40.07) | 18.06 (10.56) | p = 0.346 | 23.95 (11.94) | 24.51 (40.23) | p = 0.955 | |
| Sclerostine (pg/ml) | 12.25 (6.80) | 9.80 (6.48) | p = 0.214 | 13.29 (6.88) | 10.47 (6.51) | p = 0.096 | |
| Osteopontin (pg/ml) | 6724,19 (6366,32) | 2312,92 (2183,22) | p = 0,006 | 5922,56 (1395,96) | 5347,27(5768,54) | p = 0,976 | |
| RANKL/Opg | 3.42 (7.06) | 8.12 (22.78) | p = 0,.48 | 2.23 (7.52) | 6,.1( 16,10) | p = 0,348 | |
| BAP (U/l) | 59.56 (76.20) | 19.77 (7.76) | p = 0.032 | 28.59 (18.38) | 55.38 (77.23) | p = 0.154 | |